Alzheimer's Disease (AD) is a progressive neurodegenerative disease associated with memory loss and gradual behavioral, functional and cognitive impairment. Conventional imaging studies, such as magnetic resonance or computed tomography have played a secondary role in AD diagnosis: While other causes of memory loss and cognitive deficit can be evaluated by these imaging methods, AD structural changes are not detected until very late in the course of the disease. Recent and more precise techniques have been developed to detect subtle changes not visualized with those imaging methods. This article presents a review of the neuroimaging techniques used as a diagnostic aid for AD.
KhachaturianZS: Diagnosis of Alzheimer's disease. Arch Neurol42: 1097–1105, 1985.
2.
BraakHBraakE: Diagnostic criteria for neuropathologic assessment of Alzheimer's disease. Neurobiol Aging18: S85–88, 1997.
3.
JobstKASmithADSzatmariM: Detection in life of confirmed Alzheimer's disease using a simple measurement of medial temporal lobe atrophy by computed tomography. Lancet340: 1179–1183, 1992.
4.
GeorgeAEde LeonMJStylopoulosLA: CT diagnostic features of Alzheimer disease: importance of the choroidal/hippocampal fissure complex. Am J Neuroradiol11: 101–107, 1990.
5.
GieselFLThomannPAHahnHK: Comparison of manual direct and automated indirect measurement of hippocampus using magnetic resonance imaging. Eur J Radiol2007.
6.
ScheltensPFoxNBarkhofF: Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol1: 13–21, 2002.
7.
WahlundLOJulinPJohanssonSE: Visual rating and volumetry of the medial temporal lobe on magnetic resonance imaging in dementia: a comparative study. J Neurol Neurosurg Psychiatry69: 630–635, 2000.
8.
JackCRJr.PetersenRCO'BrienPC: MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease. Neurology42: 183–188, 1992.
9.
KohlerSBlackSESindenM: Memory impairments associated with hippocampal versus parahippocampal-gyrus atrophy: an MR volumetry study in Alzheimer's disease. Neuropsychologia36: 901–914, 1998.
10.
BaronJCChetelatGDesgrangesB: In vivo mapping of gray matter loss with voxel-based morphometry in mild Alzheimer's disease. Neuroimage14: 298–309, 2001.
JackCRJr.BentleyMDTwomeyCK: MR imaging-based volume measurements of the hippocampal formation and anterior temporal lobe: validation studies. Radiology176: 205–209, 1990.
13.
KillianyRJGomez-IslaTMossM: Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann Neurol47: 430–439, 2000.
14.
JackCRJr.PetersenRCXuYC: Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology52: 1397–1403, 1999.
15.
JackCRJr.PetersenRCXuY: Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease. Neurology51: 993–999, 1998.
16.
FoxNCCrumWRScahillRI: Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images. Lancet358: 201–205, 2001.
17.
CallenDJBlackSEGaoF: Beyond the hippocampus: MRI volumetry confirms widespread limbic atrophy in AD. Neurology57: 1669–1674, 2001.
18.
JuottonenKLaaksoMPPartanenK: Comparative MR analysis of the entorhinal cortex and hippocampus in diagnosing Alzheimer disease. Am J Neuroradiol20: 139–144, 1999.
19.
LiYLiJSegalS: Hippocampal cerebrospinal fluid spaces on MR imaging: Relationship to aging and Alzheimer disease. Am J Neuroradiol27: 912–918, 2006.
20.
Bastos-LeiteAJvan WaesbergheJHOenAL: Hippocampal sulcus width and cavities: comparison between patients with Alzheimer disease and nondemented elderly subjects. Am J Neuroradiol27: 2141–2145, 2006.
21.
IordanovaBRosenbaumDNormanD: MR imaging anatomy in neurodegeneration: a robust volumetric parcellation method of the frontal lobe gyri with quantitative validation in patients with dementia. Am J Neuroradiol27: 1747–1754, 2006.
22.
FoxNCCousensSScahillR: Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. Arch Neurol57: 339–344, 2000.
23.
MosconiL: Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging32: 486–510, 2005.
24.
ScahillRISchottJMStevensJM: Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI. Proc Natl Acad Sci USA99: 4703–4707, 2002.
25.
ValenzuelaMJSachdevP: Magnetic resonance spectroscopy in AD. Neurology56: 592–598, 2001.
26.
ChenJGCharlesHCBarboriakDP: Magnetic resonance spectroscopy in Alzheimer's disease: focus on N-acetylaspartate. Acta Neurol Scand Suppl176: 20–26, 2000.
27.
GodboltAKWaldmanADMacManusDG: MRS shows abnormalities before symptoms in familial Alzheimer disease. Neurology66: 718–722, 2006.
28.
KantarciKWeigandSDPetersenRC: Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging28: 1330–1339, 2007.
29.
MoatsRAErnstTShonkTK: Abnormal cerebral metabolite concentrations in patients with probable Alzheimer disease. Magn Reson Med32: 110–115, 1994.
30.
MillerBLMoatsRAShonkT: Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy. Radiology187: 433–437, 1993.
den HeijerTSijensPEPrinsND: MR spectroscopy of brain white matter in the prediction of dementia. Neurology66: 540–544, 2006.
33.
ModregoPJFayedNPinaMA: Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy. Am J Psychiatry162: 667–675, 2005.
34.
BozzaoAFlorisRBavieraME: Diffusion and perfusion MR imaging in cases of Alzheimer's disease: correlations with cortical atrophy and lesion load. AJNR Am J Neuroradiol22: 1030–1036, 2001.
35.
HarrisGJLewisRFSatlinA: Dynamic susceptibility contrast MR imaging of regional cerebral blood volume in Alzheimer disease: a promising alternative to nuclear medicine. Am J Neuroradiol19: 1727–1732, 1998.
36.
MaasLCHarrisGJSatlinA: Regional cerebral blood volume measured by dynamic susceptibility contrast MR imaging in Alzheimer's disease: a principal components analysis. J Magn Reson Imaging7: 215–219, 1997.
37.
AlsopDCDetreJAGrossmanM: Assessment of cerebral blood flow in Alzheimer's disease by spin-labeled magnetic resonance imaging. Ann Neurol47: 93–100, 2000.
38.
AsllaniIHabeckCScarmeasN: Multivariate and univariate analysis of continuous arterial spin labeling perfusion MRI in Alzheimer's disease. J Cereb Blood Flow Metab, 2007.
39.
DuATJahngGHHayasakaS: Hypoperfusion in frontotemporal dementia and Alzheimer disease by arterial spin labeling MRI. Neurology67: 1215–1220, 2006.
40.
HanyuHSakuraiHIwamotoT: Diffusion-weighted MR imaging of the hippocampus and temporal white matter in Alzheimer's disease. J Neurol Sci156: 195–200, 1998.
41.
KantarciKPetersenRCBoeveBF: DWI predicts future progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology64: 902–904, 2005.
42.
SandsonTAFelicianOEdelmanRR: Diffusion-weighted magnetic resonance imaging in Alzheimer's disease. Dement Geriatr Cogn Disord10: 166–171, 1999.
43.
KantarciKJackCRJr.XuYC: Mild cognitive impairment and Alzheimer disease: regional diffusivity of water. Radiology219: 101–107, 2001.
44.
StahlRDietrichOTeipelSJ: White matter damage in Alzheimer disease and mild cognitive impairment: assessment with diffusion-tensor MR imaging and parallel imaging techniques. Radiology243: 483–492, 2007.
45.
BartzokisGCummingsJLSultzerD: White matter structural integrity in healthy aging adults and patients with Alzheimer disease: a magnetic resonance imaging study. Arch Neurol60: 393–398, 2003.
46.
RoseSEChenFChalkJB: Loss of connectivity in Alzheimer's disease: an evaluation of white matter tract integrity with colour coded MR diffusion tensor imaging. J Neurol Neurosurg Psychiatry69: 528–530, 2000.
47.
TaokaTIwasakiSSakamotoM: Diffusion anisotropy and diffusivity of white matter tracts within the temporal stem in Alzheimer disease: evaluation of the „tract of interest” by diffusion tensor tractography. AJNR Am J Neuroradiol27: 1040–1045, 2006.
48.
BookheimerSYStrojwasMHCohenMS: Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med343: 450–456, 2000.
49.
RomboutsSABarkhofFVeltmanDJ: Functional MR imaging in Alzheimer's disease during memory encoding. AJNR Am J Neuroradiol21: 1869–1875, 2000.
50.
MachuldaMMWardHABorowskiB: Comparison of memory fMRI response among normal, MCI, and Alzheimer's patients. Neurology61: 500–506, 2003.
51.
DickersonBCSalatDHGreveDN: Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology65: 404–411, 2005.
SmallGWErcoliLMSilvermanDH: Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA97: 6037–6042, 2000.
54.
RomboutsSScheltensP: Functional connectivity in elderly controls and AD patients using resting state fMRI: a pilot study. Curr Alzheimer Res2: 115–116, 2005.
55.
RomboutsSABarkhofFGoekoopR: Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: an fMRI study. Hum Brain Mapp26: 231–239, 2005.
56.
GreiciusMDKrasnowBReissAL: Functional connectivity in the resting brain: a network analysis of the default mode hypothesis. Proc Natl Acad Sci USA100: 253–258, 2003.
57.
RaichleMEMacLeodAMSnyderAZ: A default mode of brain function. Proc Natl Acad Sci U S A98: 676–682, 2001.
58.
LustigCSnyderAZBhaktaM: Functional deactivations: change with age and dementia of the Alzheimer type. Proc Natl Acad Sci USA100: 14504–14509, 2003.
59.
BensonDFKuhlDEHawkinsRA: The fluorodeoxyglucose 18F scan in Alzheimer's disease and multi-infarct dementia. Arch Neurol40: 711–714, 1983.
60.
FriedlandRPBudingerTFGanzE: Regional cerebral metabolic alterations in dementia of the Alzheimer type: positron emission tomography with [18F]fluorodeoxyglucose. J Comput Assist Tomogr7: 590–598, 1983.
61.
JagustWJBudingerTFReedBR: The diagnosis of dementia with single photon emission computed tomography. Arch Neurol44: 258–262, 1987.
62.
MatsudaH: Role of neuroimaging in Alzheimer's disease, with emphasis on brain perfusion SPECT. J Nucl Med48: 1289–1300, 2007.
63.
MinoshimaSGiordaniBBerentS: Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol42: 85–94, 1997.
64.
JagustWReedBMungasD: What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?Neurology69: 871–877, 2007.
65.
BonteFJWeinerMFBigioEH: Brain blood flow in the dementias: SPECT with histopathologic correlation in 54 patients. Radiology202: 793–797, 1997.
66.
ReimanEMCaselliRJYunLS: Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med334: 752–758, 1996.
67.
AgdeppaEDKepeVLiuJ: Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthyl-ethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J Neurosci21: RC189, 2001.
68.
Shoghi-JadidKSmallGWAgdeppaED: Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry10: 24–35, 2002.
69.
AgdeppaEDKepeVLiuJ: 2-Dialkylamino-6-acylmalononitrile substituted naphthalenes (DDNP analogs): novel diagnostic and therapeutic tools in Alzheimer's disease. Mol Imaging Biol5: 404–417, 2003.
70.
KlunkWEEnglerHNordbergA: Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol55: 306–319, 2004.
71.
RoweCCNgSAckermannU: Imaging beta-amyloid burden in aging and dementia. Neurology68: 1718–1725, 2007.
72.
NewbergABWinteringNAPlosslK: Safety, biodistribution, and dosimetry of 123I-IMPY: a novel amyloid plaque-imaging agent for the diagnosis of Alzheimer's disease. J Nucl Med47: 748–754, 2006.
73.
WangYKlunkWEDebnathML: Development of a PET/SPECT agent for amyloid imaging in Alzheimer's disease. J Mol Neurosci24: 55–62, 2004.
74.
BenvenisteHEinsteinGKimKR: Detection of neuritic plaques in Alzheimer's disease by magnetic resonance microscopy. Proc Natl Acad Sci USA96: 14079–14084, 1999.
75.
HuesgenCTBurgerPCCrainBJ: In vitro MR microscopy of the hippocampus in Alzheimer's disease. Neurology43: 145–152, 1993.
76.
HelpernJALeeSPFalangolaMF: MRI assessment of neuropathology in a transgenic mouse model of Alzheimer's disease. Magn Reson Med51: 794–798, 2004.
77.
LeeSPFalangolaMFNixonRA: Visualization of beta-amyloid plaques in a transgenic mouse model of Alzheimer's disease using MR microscopy without contrast reagents. Magn Reson Med52: 538–544, 2004.
78.
ZhangJYarowskyPGordonMN: Detection of amyloid plaques in mouse models of Alzheimer's disease by magnetic resonance imaging. Magn Reson Med51: 452–457, 2004.
79.
JackCRJr.MarjanskaMWengenackTM: Magnetic resonance imaging of Alzheimer's pathology in the brains of living transgenic mice: a new tool in Alzheimer's disease research. Neuroscientist13: 38–48, 2007.
80.
JackCRJr.WengenackTMReyesDA: In vivo magnetic resonance microimaging of individual amyloid plaques in Alzheimer's transgenic mice. J Neurosci25: 10041–10048, 2005.
